[
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.Individual and Biological Factors\nMolecular, Cellular, and Physiologic Levels\nGenomic Ancestry and Risk Variants\nGermline and tumor molecular variations represent a landscape in which disparities may arise.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.Supplementary Material\n\nSupplementary Table S1Table S1: Key directions to consider\n\n\nbcd-24-0153_supplementary_table_s1_suppst1.docx (20.8KB, docx) \n\nSupplementary Table S2Supplementary Table S2: Funding Resources to Address Disparities\n\n\nbcd-24-0153_supplementary_table_s2_suppst2.docx (18.6KB, docx) \nAcknowledgments\nWe thank Sikander Ailawadhi, Hearn Cho, Melissa Davis, Ann-Kathrin Eisfeld, Olivier Elemento, Meghan Guiterrez, Lee Greenberger, Monique Hartley-Brown, Justine Kahn, Arnold Levine, Scarlett Lin-Gomez, Luis Malpica, Catherine Marinac, Stephen Nimer, Erica Phillips, Adam-de Smith, Ankur Singh, Tiffany Wallace, Jedd Wolchok, Twanda Frazier, Byron Daily, and Paula Ngon for data, ideas, insights, and discussions that have contributed toward developing this review.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 displays an application of the multilevel “Cells-to-Society” model to hematologic cancers (3, 4, 14, 15).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This search identified 209 articles, with 79, 70, and 61 involving leukemia, lymphoma, and myeloma, respectively; one study was common to both leukemia and lymphoma (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Based on the multilevel framework depicted in Fig. 1, we discuss the factors that influence disparities in hematologic malignancies at individual and biological levels, society and community levels, and system levels.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nCollaborative model for addressing health disparities. ‡, Investigators need to address unique characteristics of hematologic malignancies in underrepresented populations via experimental and clinical trials. **, Data sharing and patient and student/trainee outreach and retention. *, Engage in care delivery (e.g., home health assistance and visiting nurses, remote clinical trials, transport provision); increased communication with patients (e.g., text messaging, email, phone, or paper); account for patient experience in process and trial design. #, Determine barriers to care by monitoring billing patterns. §, Expand public health insurance coverage; develop a robust interconnected data infrastructure and improve collaborations across federal government bodies; support funding for development of new therapeutics, outreach programs, and retention of minorities in the workforce. †, Support funding for research and development of new therapeutics, population studies, outreach programs, and retention of minorities in the workforce.Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We underscore the complexity of cancer disparities and champion a collaborative, multidimensional strategy rooted in merging scientific evidence (genetics, biology, experimental therapeutics, and population studies) with engagement at multiple levels involving healthcare systems, local and federal policymakers, and funding agencies (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Future Directions\nProactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Proactive strategies to address hematologic disparities include the following: (i) establish a holistic approach to combine expertise from academia, government, insurers, policymakers, and communities (Fig. 3); (ii) understand the biological intricacies of hematologic malignancies across affected populations to tailor precise interventions; (iii) define modifiable (e.g., obesity, smoking, etc.) and nonmodifiable (genetic) risk factors that contribute to disparities and their underlying causes, including how they interact with societal factors; (iv) harness the power of research and policy to address structural barriers hindering access to high-quality education, healthcare, and socioeconomic stability; (v) evaluate funding allocations and care delivery, ensuring every patient receives gold-standard treatment, regardless of background; and (vi) improve healthcare coverage, physician and patient education, and outreach via collaboration between insurance providers, healthcare providers, and governing bodies.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]